Cervical cancer in pregnancy: a case report
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20242657Keywords:
Cervical cancer, Pregnancy, Maternal health, Obstetrics, GynecologyAbstract
Cancers during pregnancy are uncommon, with the latest mothers and babies: reducing risk through audits and confidential enquiries across the UK (MBRRACE) report (2023) indicating cancers account for 2% of maternal deaths, highlighting the need for early detection. Cervical cancer, the most common gynecological malignancy in pregnancy, has an incidence of 0.1 to 12.0 per 10,000 pregnancies. The human papillomavirus (HPV) vaccination is expected to significantly reduce cervical cancer rates. We present a case of a 37-year-old multiparous woman with cervical cancer who declined investigations during pregnancy. A white-British woman in her mid-30s presented at 19 weeks gestation with vaginal bleeding. She had low compliance with cervical screening. Despite multiple referrals, she declined urgent colposcopy. At 38 weeks, she had a spontaneous rupture of membranes but did not progress in labor. A cesarean section revealed no tumor in the lower segment. Postnatal examination identified invasive cervical cancer extending to the anterior vagina. Magnetic resonance imaging (MRI) and positron emission tomography-computed tomography (PET-CT) confirmed stage IIIC1r cervical cancer. The patient underwent successful cisplatin-based chemoradiotherapy and was tumor-free at the three-month review. Cervical screening is crucial for early cancer detection and intervention. Reduced participation in screening programs increases the incidence of advanced-stage cervical cancer. Managing patients who decline screening requires a compassionate approach and strategic efforts to encourage compliance. Physiological changes during pregnancy can obscure cancer symptoms, leading to delayed diagnoses and limited treatment options due to fetal risks. Advanced cervical cancer treatment during pregnancy often involves chemotherapy, with radical surgery considered for patients responding well to induction chemotherapy. Evolving follow-up strategies suggest prolonged monitoring due to delayed recurrences when chemotherapy is incorporated.
References
MBRRACE-UK. Saving Lives, Improving Mothers' Care: Lessons learned to inform maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2019-21. National Perinatal Epidemiology Unit, University of Oxford. 2023. Available at: https://www.npeu.ox.ac.uk/ mbrrace-uk/reports. Accessed on 15 May 2024.
Castanon A, Landy R, Pesola F, Windridge P, Sasieni P. Prediction of cervical cancer incidence in England, UK, up to 2040, under four scenarios: a modelling study. Lancet Pub Health. 2018;3:e34-43.
British Gynaecological Cancer Society. British Gynaecological Cancer Society (BGCS) cervical cancer guidelines: Recommendations for practice. 2020. Available at: https://www.bgcs.org.uk/wp-content/uploads/2020/05/FINAL-Cx-Ca-Version-for-submission.pdf. Accessed on 15 May 2024.
Mori T, Hosokawa K, Kinoshita Y, Watanabe A, Honjo H. Neoadjuvant chemotherapy with weekly carboplatin and paclitaxel for locally advanced cervical carcinoma. Int J Gynecol Cancer. 2008;18(1):85-9.
Miccò M, Lupinelli M, Mangialardi M, Gui B, Manfredi R. Patterns of Recurrent Disease in Cervical Cancer. J Pers Med. 2022;12(5):755.
Song KQ, Di W. Advances in the Diagnosis and Treatment of Pregnancy Complicated with Cervical Disease. J Int Obstet Gynecol. 2017;44:356-60.
Amant F, Halaska MJ, Fumagalli M. Gynecologic cancers in pregnancy: guidelines of a second international consensus meeting. Int J Gynecol Cancer. 2014;24:394-403.
Amant F, Berveiller P, Boere IA, Cardonick E, Fruscio R, Fumagalli M, et al. Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting. Ann Oncol. 2019;30(10):1601-12.
